首页> 美国卫生研究院文献>other >The Management of Cognitive Impairment in Bipolar Disorder: Current Status and Perspectives
【2h】

The Management of Cognitive Impairment in Bipolar Disorder: Current Status and Perspectives

机译:双相情感障碍认知障碍的治疗:现状和观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bipolar disorder (BD) is associated with important cognitive deficits that persist during the periods of remission. Although these deficits seem to play an important role in the functional impairment experienced by bipolar patients, evidence regarding their clinical management is scant. We revised the databases PubMed, MEDLINE, and , searching for studies focusing on the pharmacological and nonpharmacological treatment of cognitive deficits among bipolar patients. In addition, a manual search of bibliographical cross-references was performed. Currently, there is no Food and Drug Administration–approved pharmacological agent for the management of cognitive deficits in BD. A number of agents have been tested in the treatment of cognitive deficits in BD, with mixed results. Nonpharmacological interventions, such as cognitive remediation and noninvasive brain stimulation techniques, seem promising, but their role has not yet been properly explored among bipolar patients. Additional studies, aiming at evaluating the efficacy of interventions combining cognitive rehabilitation and biological treatments, are highly desirable.
机译:躁郁症(BD)与重要的认知缺陷有关,这种缺陷在缓解期间持续存在。尽管这些缺陷似乎在躁郁症患者的功能障碍中起重要作用,但有关其临床管理的证据很少。我们修订了PubMed,MEDLINE和的数据库,以寻找侧重于双相型患者认知障碍的药物和非药物治疗的研究。此外,还对书目参考进行了手动搜索。当前,尚无食品和药物管理局批准的用于治疗BD认知缺陷的药理剂。在治疗BD认知缺陷中已经测试了多种药物,但结果好坏参半。诸如认知矫正和非侵入性脑刺激技术之类的非药物干预措施似乎很有希望,但尚未在双相型患者中正确地探讨其作用。迫切需要进行其他研究,以评估将认知康复和生物治疗相结合的干预措施的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号